Skip to main content

Use of PYLARIFY® in Specific Patient Groups

Videos — November 23, 2021
Neal Shore, MD, FACS
Carolina Urologic Research Center
Myrtle Beach, SC
Dr Neal Shore highlights example patient populations that may benefit from improved staging through the use of PYLARIFY® (piflufolastat F 18), a prostate-specific membrane antigen (PSMA)-targeted PET/CT agent.

Related Items